In EGFR mutant NSCLC cell lines, the treatment with statins was shown to augment the anti-tumor effects of ACLY inhibition; this effect was attributed to the inhibition of PI3K/AKT and MAPK pathways [114]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.